Volume 39, Issue 8 pp. 1544-1549
Original Article

Outcomes for patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer

Babak Tamjid FRACP

Corresponding Author

Babak Tamjid FRACP

Department of Oncology, Goulburn Valley Health, Shepparton, Australia

Department Medical Oncology and Clinical Haematology, Olivia Newton John Cancer Research Institute, Austin Hospital, Melbourne, Australia

Corresponding author: B. Tamjid, Department of Oncology, Goulburn Valley Health, Graham Street, Shepparton, Australia 3630. E-mail: [email protected]Search for more papers by this author
Phuong Phan MBBS

Phuong Phan MBBS

Department Medical Oncology and Clinical Haematology, Olivia Newton John Cancer Research Institute, Austin Hospital, Melbourne, Australia

Search for more papers by this author
Thomas John FRACP, PhD

Thomas John FRACP, PhD

Department Medical Oncology and Clinical Haematology, Olivia Newton John Cancer Research Institute, Austin Hospital, Melbourne, Australia

Search for more papers by this author
Paul Mitchell MD

Paul Mitchell MD

Department Medical Oncology and Clinical Haematology, Olivia Newton John Cancer Research Institute, Austin Hospital, Melbourne, Australia

Search for more papers by this author
Hui Gan FRACP, PhD

Hui Gan FRACP, PhD

Department Medical Oncology and Clinical Haematology, Olivia Newton John Cancer Research Institute, Austin Hospital, Melbourne, Australia

Search for more papers by this author
First published: 07 June 2017
Citations: 5

ABSTRACT

Background

Not-infrequently patients with head and neck cancer are also diagnosed with synchronous lung cancer or metachronous primary lung cancer, which complicates the treatment decisions and prognosis.

Methods

Patients were identified from a database of patients with head and neck cancer with second primary non-small cell lung cancer (NSCLC).

Results

Thirty-four eligible patients (15 with synchronous lung cancer and 19 with metachronous lung cancer) were identified. Thirteen of 15 patients with synchronous lung cancer received curative intent treatment for head and neck cancer first. Six of 15 patients were in complete remission, 5 of 15 patients had died, and 4 were alive with progressive disease. Median time between 2 diagnoses was 47 months in the metachronous lung cancer group. Twelve patients had died, 3 were alive with disease, and 4 were lost to follow-up. Median survival from the time of lung cancer diagnosis was 13 months with a trend to better survival with synchronous lung cancer (15 vs 11 months; p = .11).

Conclusion

Aggressive multidisciplinary management of second primary lung malignancies in patients with head and neck cancer can result in respectable long-term disease control particularly in patients with synchronous lung cancer. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1544–1549, 2017

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.